GETECCU-2005 recommendations for the use of infliximab (Remicade®) in inflammatory bowel disease;Recomendaciones GETECCU-2005 para el uso de infliximab (Remicade®) en la enfermedad inflamatoria intestinal

Gastroenterologia y Hepatologia

Volumn 28, Issue 3, 2005, Pages 126-134

  Domenech E ^a   Esteve, M ^b   Gomollon F ^c   Hinojosa, J ^d   Panes J ^e   Obrador, A ^f   Gassull, M A ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b HOSPITAL MÚTUA DE TERRASSA   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^d HOSPITAL DE SAGUNTO   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

^f HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; IMMUNOMODULATING AGENT; INFLIXIMAB;

CONGESTIVE HEART FAILURE; ENTERITIS; HUMAN; HYPERSENSITIVITY; IMMUNOGENICITY; INFECTION; NEUROLOGIC DISEASE; OPPORTUNISTIC INFECTION; PRACTICE GUIDELINE; REMISSION; REVIEW; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TUBERCULOSIS; VIRUS HEPATITIS;

EID: 16344372166     PISSN: 02105705     EISSN: None     Source Type: Journal    
DOI: 10.1157/13072012     Document Type: Article

References (71)

1. Domènech E, Esteve-Comas M, Gomollón F, Hinojosa J, Obrador A, Panés J, et al. Recomendaciones para el uso de infliximab (Remicade®) en la enfermedad de Crohn. GETECCU 2001. Gastroenterol Hepatol. 2002;25:162-9.
2. Targan SR, Hanauer SB, Van Deventer SJ, Mayer LI, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997;337:1029-35.
3. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer LL, Van Hozegand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999;340:1398-405.
4. Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 1999;117:761-9.
5. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LLF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-9.
6. Sands BE, Anderson FH, Bernstein CN, Che WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350:876-85.
7. Miehsler W, Reinisch W, Kazemi-Shirazi L, Dejaco C, Novacek G, Ferenci P, et al. Infliximab: lack of efficacy on perforating complications in Crohn's disease. Inflamm Bowel Dis. 2004;10:36-40.
8. Parsi MA, Lashner BA, Achkar JP, Connor JT, Brzezinski A. Type of fistula determines response to infliximab in patients with fistulous Crohn's disease. Am J Gastroenterol. 2004;99:445-9.
9. Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol. 2000;95:3469-77.
10. Farrell RJ, Shah SA, Lodhavia PJ, Alsahli M, Falchuk KR, Michetti P, et al. Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Am J Gastroenterol. 2000;95:3490-7.
11. Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: The first 100 patients. Am J Gastroenterol. 2001;96:722-9.
12. Lémman M, Colombel JF, Duclos B, Veyrac M, Dupas J, Delchier J, et al. Infliximab in steroid dependent Crohn's disease patients treated with azathioprine or 6-MP a randomised double-blind placebo-controlled trial. Gut. 2003;52 Suppl: A44.
13. Regueiro M, Valentine J, Plevy S, Fleisher MR, Lichtenstein GR. Infliximab for the treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol. 2003;98:1821-6.
14. Sheldon DG, Sawchuk LL, Kozarek RA, Thirlby RC. Twenty cases of peristomal pyoderma gangrenosum: diagnostic implications and management. Arch Surg. 2000;135:564-8.
15. Andus T, Herfarth H, Obermeier F, Kuehbacher T, Mascheretti S, Thriene W, et al. Improvement of arthritis/arthralgia after treatment with infliximab (Remicade®) in a german prospective open-label multicenter trial in refractory Crohn's disease. Gastroenterology. 2001;120 Suppl 1:A621.
16. Van den Bosch F, Kruithof E, Baeten D, De Keyser F, Mielants H, Veys EM. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis. 2000;59:428-33.
17. Van den Bosch F, Kruithof E, De Vos M, De Keyser F, Mielants H. Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet. 2000;356:1821-2.
18. Van den Bosch F, Kruithof E, Baeten D, Receñís A, De Keyser F, Mielants H, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondyloarthropathy. Arthritis Rheum. 2002;46:755-65.
19. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondilitis with infliximab: a randomised controlled multicenter trial. Lancet. 2002;359:1187-93.
20. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondilitis by inhibition of tumor necrosis factor alpha. N Engl J Med. 2002;346:1349-56.
21. Ricart E, Panaccione R, Loftus E, Tremaine WJ, Sandborn WJ. Successful management of Crohn's disease of the ileoanal pouch with infliximab. Gastroenterology. 1999;117:429-32.
22. Hyams JS, Markowitz J, Wyllie R. Use of infliximab in the treatment of Crohn's disease in children and adolescents. J Pediatr. 2000;137:192-6.
23. Kugathasan S, Werlin SL, Martínez A, et al. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am J Gastroenterol. 2000;95:3189-94.
24. Khan S, Henderson WA, Kocoshis SA, Goyal A, Di Lorenzo C. The use of infliximab in pediatric Crohn's disease. Gastroenterology. 2001;120 Suppl 1:A210.
25. Cezard JP, Nouailli N, Talbotec C, Hugot JP, Gobert JG, Schmitz J, et al. A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (Remicade®) in severe pediatric Crohn's disease. J Ped Gastroenterol Nutr. 2003;36:632-6.
26. Baldassano R, Braegger C, Escher JC, DeWoody K, Hendricks DF, Keenan GF, et al. Infliximab (Remicade®) therapy in the treatment of pediatric Crohn's disease. Am J Gastroenterol. 2003;98:833-8.
27. Kay M, Wyllie R. The real cost of pediatric Crohn's disease: the role of infliximab in the treatment of pediatric IBD. Am J Gastroenterol. 2003;98:717-20.
28. Lionetti P, Bronzini F, Salvestrini C, Bascietto C, Berni Canani R, Dé Angelis GL, et al. Response to infliximab is related to disease duration in pediatric Crohn's disease. Aliment Pharmacol Ther. 2003;18:425-31.
29. Probert CSJ, Hearing SD, Schreiber S, Kuhbacher T, Gosh S, Arnot ID, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut. 2003;52:998-1002.
30. Ochsenkun T, Sackmann M, Goeke B. Infliximab for acute severe ulcerative colitis: a randomized pilot study in non steroid refractory patients. Gastroenterology. 2003;124 Suppl 1:A62.
31. Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology. 2004;126:402-13.
32. Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomised controlled trial. Gastroenterology. 2003;124:917-24.
33. Sandborn WJ. Preventing antibodies to infliximab in patients with Crohn's disease: optimize not immunize. Gastroenterology. 2003;124:1140-5.
34. Mantzaris GJ, Ployzou P, Karagiannidis A, Christidou A, Koilakou S, Tsounis D, et al. A prospective, randomized trial of infliximab and azathioprine for the induction and maintenance of remission of steroid-dependent Crohn's disease. Gastroenterology. 2004;126 Suppl 2:A-54.
35. Van Assche G, Vanbeckevoort D, Bielen D, Coremans G, Aerden I, Noman M, et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease. Am J Gastroenterol. 2003;98:332-9.
36. Bell SJ, Halligan S, Windsor AC, Williams AB, Wiesel P, Kam MA. Response of fistulating Crohn's disease to infliximab treatment assessed by magnetic resonance imaging. Aliment Pharmacol Ther. 2003;17:387-93.
37. Van Bodegraven AA, Sloots CE, Felt-Bersma RJ, Meuwissen SG. Endosonographic evidence of persistence of Crohn's disease-associated fistulas after infliximab treatment, irrespective of clinical response. Dis Colon Rectum. 2002;45:39-46.
38. Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology. 2004;126:1593-610.
39. Baert F, Noman M, Vermeire S, Van Assche G, D'Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348:601-8.
40. Crandall WV, Mackner LM. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Aliment Pharmacol Ther. 2003;17:75-84.
41. Miele E, Markowitz JE, Mamula P, Baldassano RN. Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. J Pediatr Gastroenterol Nutr. 2004;38:502-8.
42. Kugathasan S, Levy MB, Saeian K, Vasilopoulos S, Kim JP, Prajapati D, et al. Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction. Am J Gastroenterol. 2002;97:1408-14.
43. Vermeire S, Noman M, Van Assche G, Baert F, Van Steen K, Esters N, et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology. 2003;125:32-9.
44. García-Planella E, Domènech E, Esteve-Comas M, Bernal I, Cabré E, Boix J, et al. Development of antinuclear antibodies and its clinical impact in patients with Crohn's disease treated with chimeric monoclonal anti-TNF alpha antibodies (infliximab). Eur J Gastroenterol Hepatol. 2003;15:1-4.
45. Fefferman DS, Lodhavia PJ, Alsahli M, Falchuk KR, Peppercorn MA, Shah SA, et al. Smoking habits and immunomodulators do not influence the response or duration of response to infliximab in Crohn's disease. Inflamm Bowel Dis. 2004;10:346-51.
46. Roblin X, Serre-Debeauvais F, Phelip JM, Bessardi G, Bonaz B. Drug interaction between infliximab and azathioprine in patients with Crohn's disease. Aliment Pharmacol Ther. 2003;18:917-25.
47. Colombel JF, Loftus EV Jr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients. Gastroenterology. 2004;126:19-31.
48. Ljung T, Karlén P, Schmidt D, Hellström PM, Lapidus A, Janczewska I, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stokholm County. Gut. 2004;53:849-53.
49. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha neutralizing agent. N Engl J Med. 2001;345:1098-104.
50. Obrador A, Lopez San Román A, Muñoz P, Fortún J, Gassull MA. Guía de consenso sobre tuberculosis y tratamiento de la enfermedad inflamatoria intestinal con infliximab. Gastroenterol Hepatol. 2003;26:29-33.
51. Lee JH, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Sigel JN, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthr Rheum. 2002;46:2565-70.
52. Sliffman NR, Gershon SK, Lee JH, et al. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum. 2003;48:319-24.
53. Velyos FS, Sandborn WJ. Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis-alpha therapy with infliximab for Crohn's disease. Inflamm Bowel Dis. 2004;10:657-60.
54. Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med. 2001;344:1099-100.
55. Herrlinger KR, Borutta A, Meinhardt G, Stange EF, Fellermann K. Fatal staphylococcal sepsis in Crohn's disease after infliximab. Inflamm Bowel Dis. 2004;10:655-6.
56. Campbel S, Ghosh S. Infliximab therapy for Crohn's disease in the presence of chronic hepatitis C infection. Eur J Gastroenterol. 2001;13:191-2.
57. Holtman MH, Galle PR, Neurath MF. Treatment of patients with Crohn's disease and concomitant chronic hepatitis C with chimeric monoclonal antibody to TNF. Am J Gastroenterol. 2003;98:504-5.
58. Michel M, Duvoux C, Hezode C, Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset Still's disease. J Rheumatol. 2003;30:1624-5.
59. Ostuni P, Botsios C, Punzi L, Sfriso P, Todesco S. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis. 2003;62:686-7.
60. Oniankitan O, Duvoux C, Challine D, Mallat A, Chevalier X, Pawlotsky JM, et al. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol. 2004;31:107-9.
61. García-Sánchez MV, Gómez-Camacho F, Poyato-González A, Iglesias-Flores EM, De Dios-Vega JF. Infliximab therapy in a patient with Crohn's disease and chronic hepatitis B virus infection. Inflamm Bowel Dis. 2004;10:701-2.
62. Peterson JL, Hsu FC, Simkin PA, Wener MH. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis. 2003;62:1078-82.
63. Esteve M, Saro C, González-Huix F, Suárez F, Forne M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut. 2004;53:1363-5.
64. EASL International Consensus Conference on Hepatitis B. The EASL Jury. J Hepatol. 2003;39 Suppl 1: S3-S25.
65. Bickston SJ, Lichtenstein GR, Arseneau KO, Cohen RB, Cominelli F. The relationship between infliximab treatment and lymphoma in Crohn's disease. Gastroenterology. 1999;117:1433-7.
66. Lori Brown S, Greene MH, Gershon SK, Edwards ET, Miles Braun M. Tumor necrosis factor antagonist therapy and lymphoma development. Arthr Rheum. 2002;46:3151-8.
67. Katz JA, Keenan GF, Snith DE, Lichtenstein GR. Outcome of pregnancy in patients receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Gastroenterology. 2003;124 Suppl 1:A7.
68. Sands BE, Cuffari C, Katz J, Kugathasan S, Onken J, Vitek C, et al. Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:677-92.
69. Biancone L, Pavia M, Del Vecchio Blanco G, D'Incà R, Castiglione F, De Nigris F, et al. Hepatitis B and C virus infection in Crohn's disease. Inflamm Bowel Dis. 2001;7:287-94.
70. Gaylis N. Infliximab in the treatment of an HIV positive patient with Reiter's syndrome. J Rheumatology. 2003;30:407-11.
71. Bartke U, Venten I, Kreuter A, Gabbay S, Altmeyer P, Brockmeyer NH. Human immunodeficiency virus-associated psoriasis and psoriatic artritis treated with infliximab. Br J Dermatol. 2004;150:784-6.